<DOC>
	<DOCNO>NCT02899104</DOCNO>
	<brief_summary>Categorize clinical parameter patient determinant drive physician decision make treatment selection include Radium-223 patient mCRPC .</brief_summary>
	<brief_title>Navigant Study- Treatment Patterns mCRPC ( Metastatic Castrate Resistant Prostate Cancer )</brief_title>
	<detailed_description>This chart review 200 Xofigo patient describe sequence characterize clinical parameter patient determinant drive physician decision making .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Patients diagnose bone metastatic castrationresistant prostate cancer ( mCRPC ) per medical chart . Patients least 18 year age first diagnosis mCRPC . Patients must receive least one intravenous injection Radium223 ( Xofigo ) . First injection Radium223 must start period 1January2014 30June2014 15November2014 present . Patients must minimum 12 month document followup record follow last Radium223 treatment death within 12 month last dose . Patients receive Radium223 part interventional clinical trial Actively treat , expect treat , 6 month last followup , malignancy exception nonmetastatic skin cancer lowgrade superficial bladder cancer .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>